These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 33958535)
1. Peptide-based 68Ga-PET radiotracer for imaging CD133 expression in colorectal cancer. Liu Y; Yao X; Wang C; Wang M; Wang Y; Ye M; Liu Y Nucl Med Commun; 2021 Oct; 42(10):1144-1150. PubMed ID: 33958535 [TBL] [Abstract][Full Text] [Related]
2. SPECT imaging of colorectal cancer by targeting CD 133 receptor with 99mTc-labeled monoclonal antibody. Liu Y; Jin X; Lan X; Lang J; Wen Q; An R Q J Nucl Med Mol Imaging; 2019 Jun; 63(2):216-224. PubMed ID: 27387378 [TBL] [Abstract][Full Text] [Related]
3. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391 [TBL] [Abstract][Full Text] [Related]
4. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET. Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818 [TBL] [Abstract][Full Text] [Related]
5. Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423 [TBL] [Abstract][Full Text] [Related]
6. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts. Lang J; Lan X; Liu Y; Jin X; Wu T; Sun X; Wen Q; An R Nucl Med Biol; 2015 May; 42(5):505-512. PubMed ID: 25669587 [TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Kramer-Marek G; Shenoy N; Seidel J; Griffiths GL; Choyke P; Capala J Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1967-76. PubMed ID: 21748382 [TBL] [Abstract][Full Text] [Related]
8. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963 [TBL] [Abstract][Full Text] [Related]
9. A Novel Small Cyclic Peptide-Based Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492 [TBL] [Abstract][Full Text] [Related]
10. Homodimeric peptide radiotracer [ Chen X; Zhang Z; Wang L; Zhang J; Zhao T; Cai J; Dang Y; Guo R; Liu R; Zhou Y; Wei R; Lou X; Xia F; Ma D; Li F; Dai J; Li F; Xi L Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2338-2352. PubMed ID: 38411667 [TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of Liu Q; Cai S; Ye J; Xie Q; Liu R; Qiu L; Lin J Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1826-1840. PubMed ID: 38319321 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature. Chen K; Sun X; Niu G; Ma Y; Yap LP; Hui X; Wu K; Fan D; Conti PS; Chen X Mol Imaging Biol; 2012 Feb; 14(1):96-105. PubMed ID: 21360213 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging. Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184 [TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and Biological Evaluation of Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911 [TBL] [Abstract][Full Text] [Related]
16. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy. Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029 [TBL] [Abstract][Full Text] [Related]
17. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors. Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983 [TBL] [Abstract][Full Text] [Related]
18. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976 [TBL] [Abstract][Full Text] [Related]
19. Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties. Hou H; Pan Y; Wang Y; Ma Y; Niu X; Sun S; Hou G; Tao W; Gao F Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2819-2832. PubMed ID: 38683349 [TBL] [Abstract][Full Text] [Related]
20. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]